DUBLIN--(BUSINESS WIRE)--The "Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Descriptive coverage of pipeline development activities for Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products for Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators
The report assesses the active Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered:
1. Report Introduction
2. Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products
4. Comparative Analysis
5. Pipeline Products in Clinical Stages
- Product Description
- Research and Development
-
Product Development Activities
6. Pipeline Products in Non-clinical Stages
- Product Description
- Research and Development
-
Product Development Activities
7. Therapeutic Assessment: Active Products
- Pipeline Assessment by Route of Administration
- Pipeline Assessment by Stage and Route of Administration
- Pipeline Assessment by Molecule Type
- Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline Products
- Product Description
- Research and Development
- Product Development Activities
-
Reason for dormancy/discontinuation
Companies Mentioned
- sanofi-aventis
- Novoteris
- Bayer HealthCare Pharmaceuticals
- Merck & Co
- Mallinckrodt plc
- Bayer
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2l63n8/guanylate_cyclase?w=4
